Takeaways from Benzinga’s Psychedelics Capital C

Takeaways from Benzinga’s Psychedelics Capital Conference

Last month, Benzinga held its second Psychedelics Capital Conference in Miami Beach. The conference brought together investors, panelists, curious individuals and leaders of major publicly traded psychedelic firms. Below are a few takeaways from the psychedelics conference.

Irwin Naturals plans to become a major specialty brand in mental health

Klee Irwin, CEO and founder of Irwin Naturals, stated during his keynote session that the company was focused on leveraging its profitable premium supplement and vitamin business and its household name to become the biggest specialty brand of psychedelic mental health clinics.

This keynote session and others from individuals and companies involved in this burgeoning space allowed industry peers and investors to connect with one another and share their thoughts on various subjects.

Despite Irwin Naturals being a publicly traded organization, Klee still owns majority shares in the company, which allows him to vote on reward/risk decisions. He noted that he was using capitalism to create impact in the society.

More psychedelic conferences in the future

This latest conference had almost 2,000 attendees, which is a significant increase from the less-than 1,000 attendees participating during the inaugural conference.

Attendees and panellists also had plenty of positive things to say about the conference, with many noting that they were glad they could attend in person. The number of attendees is expected to keep increasing as the popularity of psychedelics grows.

Natan Ponieman, head of psychedelic content at Benzinga, stated that the company believed that a psychedelic conference was justified, noting that there was a possibility to build substantial wealth in rising industries such as psychedelics. This alludes to another conference next year, especially if the public’s interest in the space continues to grow.

Women’s health is Felicity Pharma’s primary focus

Felicity Pharma is a biotechnology company focused on the creation of solutions for different female-specific disorders. CE Olivia Mannix views psychedelics as the ideal way to address women’s health.

Mannix explained that the biological makeup of women historically has been a hindrance, often prevented women from being included in clinical trials. This is what prompted the company to focus mainly on creating solutions for women, which explains why it is developing a proprietary drug for the treatment of premenstrual dysphoric disorder.

Currently, innovations in the development of new therapies for conditions that affect only women are lagging behind.

With plenty of companies such as Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) getting listed on some of the most enviable securities exchanges, you can bet that investor capital inflows will continue pouring into the psychedelics sector, and its onward march will gather more momentum with the passage of time.

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer